Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Ras-driven tumors, including Nf1-deficient malignancies and Kras/p53 mutant lung cancer, often resist standard treatments.
• Targeted therapies are needed to overcome treatment refractoriness in these aggressive cancers.

Purpose of the Study:

• To identify a novel targeted therapeutic strategy for Ras-driven cancers.
• To investigate the synergistic effects of proteotoxic stress-inducing agents and rapamycin in preclinical cancer models.

Main Methods:

• Utilized aggressive mouse models of Nf1-deficient malignancies and Kras/p53 mutant lung cancer.
• Administered HSP90 inhibitor IPI-504 alone and in combination with rapamycin.
• Assessed tumor regression and analyzed mechanisms involving endoplasmic reticulum (ER) stress, mitochondrial damage, oxidative stress, and glutathione levels.

Main Results:

• Combination therapy of IPI-504 and rapamycin induced significant tumor regression in aggressive mouse models.
• The synergistic effect was attributed to irresolvable ER stress, leading to catastrophic ER and mitochondrial damage.
• IPI-504 increased reactive oxygen species (ROS), while rapamycin suppressed glutathione, enhancing oxidative stress.

Conclusions:

• The combination of HSP90 inhibition and rapamycin represents a promising targeted therapeutic strategy for Ras-driven cancers.
• This approach synergistically enhances proteotoxic and oxidative stress, leading to tumor regression.
• The identified mechanism provides a paradigm for developing novel combination therapies for difficult-to-treat cancers.